How does PCSK9 gene editing work?

In vivo base editing targets PCSK9 to lower LDL

A report in The New England Journal of Medicine describes in vivo base editing using VERVE-102 for people with hypercholesterolemia, aiming to reduce low-density lipoprotein (LDL) cholesterol by editing the PCSK9 gene.

PCSK9 is a key regulator of LDL cholesterol metabolism. People who naturally carry loss-of-function variants in the PCSK9 gene tend to have lower LDL levels, which is one reason the pathway is considered a high-value target. The study’s core concept is to mimic that beneficial biology directly inside the body.

Base editing differs from traditional gene editing approaches by enabling more precise nucleotide changes without cutting and replacing DNA. In this case, the therapy is designed to edit PCSK9 in vivo, meaning patients receive a treatment intended to modify the relevant cells after administration rather than requiring ex vivo editing.

The story’s relevance for readers is that it represents a move toward longer-acting or potentially durable cholesterol lowering strategies beyond daily or frequent medications. If the editing effect is sustained and clinically meaningful, it could reduce LDL substantially and for longer periods than conventional therapies, which often require ongoing dosing.

That said, the excerpted summary provides only a high-level rationale and does not include results such as the magnitude and duration of LDL reductions, the proportion of participants achieving target reductions, or whether any safety concerns were observed. To properly gauge impact, those details—particularly around durability, off-target effects, immune reactions, and overall tolerability—would be essential.

Still, the mechanism-focused premise is clear: by leveraging the precedent of PCSK9 loss-of-function biology and applying base editing directly in the body, VERVE-102 seeks a new therapeutic route for hypercholesterolemia with the potential for sustained LDL lowering.